ArticleMolecular cancer research : MCR2019
Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- The identification of growth-promoting lncRNAs in oral cavity squamous cell carcinoma.Non-coding RNA research · 2026Article
- Review
- Goistrat: gene-of-interest-based sample stratification for the evaluation of functional differences.BMC bioinformatics · 2025Article
- p63: A Master Regulator at the Crossroads Between Development, Senescence, Aging, and Cancer.Cells · 2025Review
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade.Molecular therapy. Oncology · 2024Article
- Article
- A Systemic and Integrated Analysis of p63-Driven Regulatory Networks in Mouse Oral Squamous Cell Carcinoma.Cancers · 2023Article
- Predicting the immune microenvironment and prognosis with a anoikis - related signature in breast cancer.Frontiers in oncology · 2023Article
- The Splicing Factor PTBP1 RepressesCancer research communications · 2022Article
- A systematic and comprehensive analysis of colorectal squamous cell carcinoma: Implication for diagnosis and treatment.Cancer medicine · 2022Article
- p63 Directs Subtype-Specific Gene Expression in HPV+ Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Chordin-Like 1 Regulates Epithelial-to-Mesenchymal Transition and MetastasisFrontiers in oncology · 2022Article
- A pyroptosis-related gene signature for prognostic and immunological evaluation in breast cancer.Frontiers in oncology · 2022Article
- Article
- The functional GRHL3-filaggrin axis maintains a tumor differentiation potential and influences drug sensitivity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Multidimensional Mutational Profiling of the Indian HNSCC Sub-Population Provides IRAK1, a Novel Driver Gene and Potential Druggable Target.Frontiers in oncology · 2021Article
- The Role of Human Papilloma Virus in Dictating Outcomes in Head and Neck Squamous Cell Carcinoma.Frontiers in molecular biosciences · 2021Review
- The inhibition effect of natural food supplement active ingredients on TP63 carcinoma cell.Medical oncology (Northwood, London, England) · 2020Article
- A HPV16-related prognostic indicator for head and neck squamous cell carcinoma.Annals of translational medicine · 2020Article
- The Oncogenic Roles ofDiagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
TP63 is frequently amplified or overexpressed in primary head and neck squamous cell carcinomas (HNSCC). Nevertheless, the role of TP63 in the initiation and progression of HNSCCs is not known. Using archival HNSCC tissue sections, we found that TP63 expression is often downregulated in late-stage human HNSCCs. To establish a causal link between TP63 loss and HNSCC tumorigenesis, we developed a genetically engineered mouse model in which
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.